KR910018346A - 킬레이트화 화합물 및 그의 용도 - Google Patents

킬레이트화 화합물 및 그의 용도 Download PDF

Info

Publication number
KR910018346A
KR910018346A KR1019910005737A KR910005737A KR910018346A KR 910018346 A KR910018346 A KR 910018346A KR 1019910005737 A KR1019910005737 A KR 1019910005737A KR 910005737 A KR910005737 A KR 910005737A KR 910018346 A KR910018346 A KR 910018346A
Authority
KR
South Korea
Prior art keywords
alkyl
compound according
acid
chelate
salt
Prior art date
Application number
KR1019910005737A
Other languages
English (en)
Other versions
KR100189388B1 (ko
Inventor
시게미 세리
히로히꼬 야마우찌
마꼬또 아즈마
요지 아라따
Original Assignee
도끼 가쓰유끼
니혼메디피직스 가부시끼가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=14107923&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR910018346(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 도끼 가쓰유끼, 니혼메디피직스 가부시끼가이샤 filed Critical 도끼 가쓰유끼
Publication of KR910018346A publication Critical patent/KR910018346A/ko
Application granted granted Critical
Publication of KR100189388B1 publication Critical patent/KR100189388B1/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/37—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C07C311/38—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring having sulfur atoms of sulfonamide groups and amino groups bound to carbon atoms of six-membered rings of the same carbon skeleton
    • C07C311/39—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring having sulfur atoms of sulfonamide groups and amino groups bound to carbon atoms of six-membered rings of the same carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
    • C07C311/41—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring having sulfur atoms of sulfonamide groups and amino groups bound to carbon atoms of six-membered rings of the same carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by nitrogen atoms, not being part of nitro or nitroso groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0478—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group complexes from non-cyclic ligands, e.g. EDTA, MAG3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0478—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group complexes from non-cyclic ligands, e.g. EDTA, MAG3
    • A61K51/048—DTPA (diethylenetriamine tetraacetic acid)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C237/06—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C237/10—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by nitrogen atoms not being part of nitro or nitroso groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Optics & Photonics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Radiology & Medical Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)

Abstract

내용 없음

Description

킬레이트화 화합물 및 그의 용도
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
제1도는 In-111-B-DNS-etn-DAPA를 투여한 지 70시간 후의 간암조직 이식된 쥐의 신티그램(scintigram)을 나타낸다.

Claims (14)

  1. 하기 일반식(Ⅰ)의 킬레이트화 화합물 또는 그의 염 :
    (R-NHOC-CH2)n-A-(CH2COOH)m(Ⅰ)
    〔식중, R은 방향족 고리-함유 유기기이고, A는 아세트산기(-CH2COOH)가 배제된 아미노폴리아세트산 잔기이며, m은 2이상의 정수이고, n은 1 또는 2는 정수이다〕.
  2. 제1항에 있어서, 방향족 고리-함유 유기기가, 아릴부분이 저급알킬, 저급 알킬아미노 또는 디 (저급) 알킬아미노에 의해 임의로 치환된 페닐 또는 나프틸인 아릴, 아르 (저급) 알킬, 아릴술포닐, 아르 (저급) 알킬술포닐, 아릴아미노 (저급)알킬, 아르 (저급) 알킬, 아미노 (저급) 알킬 아실술포닐아미노 (저급) 알킬 또는 아르 (저급) 알킬술포닐아미노 (저급) 알킬인 화합물 또는 그의 염.
  3. 제1항에 있어서, 방향족 고리-함유 유기기가, 단실인 화합물 또는 그의 염.
  4. 제1항에 있어서, 방향족 고리-함유 유기기가, 단실아미노 (저급) 알킬인 화합물 또는 그의 염.
  5. 제1항에 있어서, 아미노폴리아세트산이 직쇄, 측쇄 또는 고리형의 탄화수소 사슬, 탄화수소 사슬내 및/또는 말단 위치에 존재하는 2이상의 아미노기 및 상기 아미노기내 질소 원자에 각각 결합된 3이상의 아세트산기(-CH2COOH)를 함유하는 화합물 또는 그의 염.
  6. 제1항에 있어서, 아미노폴리아세트산인 에틸렌디아민-테트라아세트산 (EDTA), 디에틸렌트리아민-펜타아세트산(DAPA), 트랜스-1,2-시클로헥사디아민-테트라아세트산(CyDTA) 또는 1,4,7,10-테트라아자시클로도데칸-테트라아세트산(DOTA)인 화합물 또는 그의 염.
  7. 제1항 내지 제6항중 어느 한 항에 따른 화합물 및 킬레이트 결합을 통해 결합된 금속 원소를 함유하는 킬레이트 화합물.
  8. 제7항에 있어서, 금속원자가 방사능 원소인 킬레이트 화합물.
  9. 제8항에 있어서, 방사능 원소가 테크네튬-99m, 인듐-111, 레늄-186, 레늄-188 또는 이트륨-90인 킬레이트 화합물.
  10. 제7항에 있어서, 금속 원소가 상자성 원소인 킬레이트 화합물.
  11. 제10항에 있어서, 상자성 원소가 가돌리늄인 킬레이트 화합물.
  12. 제1항에 내지 제6항중 어느 한 항에 따른 킬레이트화 화합물을 함유하며 킬레이트 형성능 및 간담즙성 기관 또는 조직에 대해 특이성을 갖는, 금속원소에 대한 담체.
  13. 제7항에 내지 제11항중 어느 한 항에 따른 킬레이트 화합물을 함유하는, 간담즙성 기관 또는 조직에 대한 진단제.
  14. 제7항에 내지 제11항중 어느 한 항에 따른 킬레이트 화합물을 함유하는, 간담즙성 기관 또는 조직에 대한 치료제.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019910005737A 1990-04-10 1991-04-10 킬레이트화 화합물 및 그의 용도 KR100189388B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP94353/1990 1990-04-10
JP094353/1990 1990-04-10
JP2094353A JP2776953B2 (ja) 1990-04-10 1990-04-10 多官能性金属キレート化合物とその用途

Publications (2)

Publication Number Publication Date
KR910018346A true KR910018346A (ko) 1991-11-30
KR100189388B1 KR100189388B1 (ko) 1999-06-01

Family

ID=14107923

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019910005737A KR100189388B1 (ko) 1990-04-10 1991-04-10 킬레이트화 화합물 및 그의 용도

Country Status (10)

Country Link
US (2) US5196576A (ko)
EP (1) EP0451824B1 (ko)
JP (1) JP2776953B2 (ko)
KR (1) KR100189388B1 (ko)
AT (1) ATE134190T1 (ko)
AU (1) AU634645B2 (ko)
CA (1) CA2040204C (ko)
DE (1) DE69117084T2 (ko)
DK (1) DK0451824T3 (ko)
ES (1) ES2085924T3 (ko)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2807852B2 (ja) * 1991-07-18 1998-10-08 株式会社ミドリ十字 新規キレート化剤、該キレート化剤と金属原子との錯化合物及びそれを含む診断剤
TW213864B (ko) * 1991-08-01 1993-10-01 Squibb & Sons Inc
ATE210464T1 (de) * 1992-06-09 2001-12-15 Neorx Corp BIOTIN-DOTA KONJUGATE UND DEREN VERWENDUNG IN ßPRETARGETINGß VERFAHREN
US5911969A (en) 1992-06-09 1999-06-15 Neorx Corporation Pretargeting protocols for enhanced localization of active agents to target sites
US5541287A (en) * 1992-06-09 1996-07-30 Neorx Corporation Pretargeting methods and compounds
US5578287A (en) * 1992-06-09 1996-11-26 Neorx Corporation Three-step pretargeting methods using improved biotin-active agent
US6358490B2 (en) 1992-06-09 2002-03-19 Neorx Corporation Three-step pretargeting methods and compounds
US6022966A (en) * 1993-11-22 2000-02-08 Neorx Corporation Pretargeting methods and compounds
EP0603403B2 (en) * 1992-07-03 2001-06-27 Welfide Corporation Novel chelating agent, complex compound composed of said agent and metallic atom, and diagnostic agent containing said compound
US5807535A (en) * 1992-07-31 1998-09-15 Australian Nuclear Science & Technology Organisation Metal complexes of hydroxyaryl containing aminocarboxylic acid chelating agents
PT590766E (pt) * 1992-07-31 2000-07-31 Australian Nuclear Science Tec Complexos metalicos de hidroxiarilo contendo agentes quelantes de acido aminocarboxilico
US6908903B1 (en) 1994-12-07 2005-06-21 Aletheon Pharmaceuticals, Inc. Cluster clearing agents
US6172045B1 (en) 1994-12-07 2001-01-09 Neorx Corporation Cluster clearing agents
US5955605A (en) * 1995-02-21 1999-09-21 Neorx Corporation Biotinidase resistant biotin-DOTA conjugates
EP1033471B1 (en) 1999-03-02 2003-09-17 Rohm And Haas Company Improved recovery and transportation of heavy crude oils
DE10002939C1 (de) * 2000-01-13 2001-09-20 Schering Ag Paramagnetische DOTA-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung für die Herstellung von pharmazeutischen Mitteln
IL145210A (en) 2000-12-06 2011-12-29 Aposense Ltd Materials that bind shaken membranes
IL147812A0 (en) * 2001-03-16 2002-08-14 N S T Neurosurvival Technologi Method for targeting chemical compounds to cells and pharmaceutical compositions used therein
IL153183A (en) 2002-06-04 2010-05-17 Aposense Ltd Agents for imaging and diagnostic methods using them
WO2004075925A1 (ja) * 2003-02-27 2004-09-10 Kyushu Tlo Company Limited Ｍｒｉ用造影剤
EP1793866A1 (en) 2004-08-26 2007-06-13 Mallinckrodt, Inc. Luminescent metal complexes for monitoring renal function
JP5338676B2 (ja) 2007-11-12 2013-11-13 三洋電機株式会社 非水電解質二次電池負極材、非水電解質二次電池用負極及び非水電解質二次電池
US10050272B2 (en) 2013-12-25 2018-08-14 Shin-Etsu Chemical Co., Ltd. Negative electrode active material for non-aqueous electolyte secondary battery and method of producing the same

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH607920A5 (ko) * 1976-05-31 1978-12-15 Solco Basel Ag
US4352751A (en) * 1979-09-10 1982-10-05 Analytical Radiation Corporation Species-linked diamine triacetic acids and their chelates
US4418208A (en) * 1980-12-29 1983-11-29 E. R. Squibb & Sons, Inc. N-Substituted iminodiacetic acids
US4647447A (en) * 1981-07-24 1987-03-03 Schering Aktiengesellschaft Diagnostic media
US4957939A (en) * 1981-07-24 1990-09-18 Schering Aktiengesellschaft Sterile pharmaceutical compositions of gadolinium chelates useful enhancing NMR imaging
JPS5828718A (ja) * 1981-08-14 1983-02-19 Toyo Contact Lens Co Ltd ソフトコンタクトレンズ
US4454107A (en) * 1982-08-30 1984-06-12 Merck & Co., Inc. Tc99m-Phenida, radioscintigraphic agent for diagnosis of hepatoniliary disease
US4943523A (en) * 1984-01-30 1990-07-24 Enzo Biochem, Inc. Detectable molecules, method of preparation and use
IL83966A (en) * 1986-09-26 1992-03-29 Schering Ag Amides of aminopolycarboxylic acids and pharmaceutical compositions containing them
US4843062A (en) * 1987-12-23 1989-06-27 American Home Products Corporation N-acyl-N-napthoylglycines as aldose reductase inhibitors
JP2815615B2 (ja) * 1988-06-07 1998-10-27 日本メジフィジックス株式会社 ジエチレントリアミン五酢酸誘導体とその用途

Also Published As

Publication number Publication date
US5138039A (en) 1992-08-11
JPH03291260A (ja) 1991-12-20
DE69117084T2 (de) 1996-10-02
JP2776953B2 (ja) 1998-07-16
CA2040204C (en) 2002-07-02
ATE134190T1 (de) 1996-02-15
EP0451824B1 (en) 1996-02-14
US5196576A (en) 1993-03-23
DK0451824T3 (da) 1996-03-11
ES2085924T3 (es) 1996-06-16
KR100189388B1 (ko) 1999-06-01
AU634645B2 (en) 1993-02-25
EP0451824A3 (en) 1992-09-02
AU7428191A (en) 1991-10-17
DE69117084D1 (de) 1996-03-28
EP0451824A2 (en) 1991-10-16
CA2040204A1 (en) 1991-10-11

Similar Documents

Publication Publication Date Title
KR910018346A (ko) 킬레이트화 화합물 및 그의 용도
NO952111D0 (no) Hepatobiliære magnetisk resonans-kontrast midler
DE69132363T2 (de) Chelat-zubereitung, die alpha-diamin-verbindungen enthalten
DK0447285T3 (da) Nephtalenderivater, fremgangsmåde til fremstilling heraf og farmaceutiske midler indeholdende dem
AR004670A1 (es) Compuestos derivados de acido amino sustituido arilo y heteroarilo carboxilico; composicion farmaceutica que los contiene; metodo para aliviar eldolor; procedimiento para preparar dichos compuestos y compuestos utiles como material de partida
PH30934A (en) Alkyl phosphonate polyazamacrocyclic chelates for mri.
DE69803148D1 (de) Kosmetische Zusammensetzungen enthaltend ein filmbildendes Polymer
KR940018398A (ko) 혈관 질병 진단제
ATE123955T1 (de) Radiopharmazeutische zusammensetzungen, verabreichungsmethode und verfahren zur herstellung derselben.
PT92157B (pt) Processo para a preparacao de quelantes, que posuuem um grupo funcional ligado na posicao orto, e de seus complexos
SE8505716D0 (sv) Novel compounds and conjugates thereof
EP0998946A1 (en) Non-porphyrin compound for use as a diagnosticum and/or pharmaceutical
ATE136292T1 (de) Sechsbindige liganden für radiographische abbildungsagenzien
ES8202003A1 (es) Un procedimiento para la preparacion de derivados de ergoli-na
US5274082A (en) Paramagnetic complexes of chelating compounds
CA1187897A (en) N-substituted iminodiacetic acids
KR960700761A (ko) 방사활성 동위원소에 대한 s_3n_2 유형의 킬레이트화제, 그의 금속 착물, 및 그의 진단 및 치료학적 용도(type s_3n_2 chelators for radioactive isotopes, their metal complexes and their diagnostic and therapeutical use)
DE69011235D1 (de) Derivate von N-(Vincristinyl-23) und N-(Noranhydro-5-vinblastinyl-23) von Amino-1-methylphosphonsäure, ihre Verfahren zur Herstellung und sie enthaltende pharmazeutische Zusammensetzungen.
AR241163A2 (es) Procedimiento para obtener derivados de chartreusina y compuestos intermediarios de aplicacion exclusiva en dicho procedimiento
FI891468A (fi) Tc-99m-w-alkylfosfiniko-1 -hydroxialkan-1,1-difosfonat innehaollande preparat foer benskintigrafi och framstaellningsfoerfarande foer detta preparat.

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
G170 Re-publication after modification of scope of protection [patent]
G170 Re-publication after modification of scope of protection [patent]
FPAY Annual fee payment

Payment date: 20060110

Year of fee payment: 8

LAPS Lapse due to unpaid annual fee